Merck & Co., Inc.
Merck (MRK) Wins FDA Nod For New Keytruda Bladder Cancer Use
·Consolidated from 4 sources
{ "headline": "Merck's Keytruda Gains New FDA Approval for Bladder Cancer", "summary": "Merck & Co. has received FDA approval for Keytruda to treat a new form of bladder cancer. This marks another expansion of Keytruda's indications. The company also presented new data on its HIV pipeline.", "article": "Merck & Co. announced today that its cornerstone cancer immunotherapy, Keytruda, has secured a new approval from the U.S
{ "headline": "Merck's Keytruda Gains New FDA Approval for Bladder Cancer", "summary": "Merck & Co. has received FDA approval for Keytruda to treat a new form of bladder cancer. This marks another expansion of Keytruda's indications. The company also presented new data on its HIV pipeline.", "article": "Merck & Co. announced today that its cornerstone cancer immunotherapy, Keytruda, has secured a new approval from the U.S
Sources
This recap was generated by consolidating the public headlines below.
- Merck (MRK) Wins FDA Nod For New Keytruda Bladder Cancer UseJul 15, 2026
- Slate Medicines Strengthens Board of Directors with Appointment of Mark W. HahnJul 15, 2026
- Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026Jul 15, 2026
- KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to ChemotherapyJul 15, 2026